SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-23-000129
Filing Date
2023-06-05
Accepted
2023-06-05 14:24:49
Documents
16
Period of Report
2023-06-05
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20230605.htm   iXBRL 8-K 44422
2 EX-99.1 ex991-smith_asco2023xznx.htm EX-99.1 9885
3 EX-99.2 ex992-liuetalasco2023.htm EX-99.2 18832
7 ex991-smith_asco2023xznx001.jpg GRAPHIC 296358
8 ex992-liuetalasco2023001.jpg GRAPHIC 205205
  Complete submission text file 0001725160-23-000129.txt   920530

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20230605.xsd EX-101.SCH 1902
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20230605_lab.xml EX-101.LAB 24849
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20230605_pre.xml EX-101.PRE 13046
10 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20230605_htm.xml XML 11258
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 23992035
SIC: 2834 Pharmaceutical Preparations